Thalassemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Thalassemia stocks.

Thalassemia Stocks Recent News

Date Stock Title
Nov 1 ALNY Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
Nov 1 ALNY Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Nov 1 ALNY Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Nov 1 ALNY Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
Nov 1 ALNY Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Oct 31 ALNY Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
Oct 31 ALNY Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
Oct 31 ALNY Alnylam: Q3 Earnings Snapshot
Oct 31 ALNY Alnylam Pharmaceuticals Non-GAAP EPS of -$0.50 misses by $0.11, revenue of $500.92M misses by $26.1M
Oct 31 ALNY Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
Oct 31 BEAM Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology
Oct 31 BLUE bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies
Oct 30 ALNY Alnylam Pharmaceuticals Q3 2024 Earnings Preview
Oct 30 ALNY Cognizant signs deal to enhance Alnylam’s IT infrastructure
Oct 30 BEAM CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
Oct 30 ALNY Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
Oct 29 BEAM Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
Oct 28 ALNY Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
Thalassemia

Thalassemias are inherited blood disorders characterized by decreased hemoglobin production. Symptoms depend on the type and can vary from none to severe. Often there is mild to severe anemia (low red blood cells or hemoglobin). Anemia can result in feeling tired and pale skin. There may also be bone problems, an enlarged spleen, yellowish skin, and dark urine. Slow growth may occur in children.Thalassemias are genetic disorders inherited from a person's parents. There are two main types, alpha thalassemia and beta thalassemia. The severity of alpha and beta thalassemia depends on how many of the four genes for alpha globin or two genes for beta globin are missing. Diagnosis is typically by blood tests including a complete blood count, special hemoglobin tests, and genetic tests. Diagnosis may occur before birth through prenatal testing.Treatment depends on the type and severity. Treatment for those with more severe disease often includes regular blood transfusions, iron chelation, and folic acid. Iron chelation may be done with deferoxamine, deferasirox or deferiprone. Occasionally, a bone marrow transplant may be an option. Complications may include iron overload from the transfusions with resulting heart or liver disease, infections, and osteoporosis. If the spleen becomes overly enlarged, surgical removal may be required. Thalassemia patients who do not respond well to blood transfusions can take hydroxyurea or thalidomide, and sometimes a combination of both. Hydroxyurea is the only FDA approved drug for thalassemia. Patients who took 10 mg/kg of hydroxyurea everyday for a year had significantly higher hemoglobin levels and it was a well-tolerated treatment for patients who did not respond well to blood transfusions. Another hemoglobin-inducer includes thalidomide, although it has not been tested in a clinical setting. The combination of thalidomide and hydroxyurea resulted in hemoglobin levels increasing significantly in transfusion-dependent and non-transfusion dependent patients As of 2015, thalassemia occurs in about 280 million people, with about 439,000 having severe disease. It is most common among people of Italian, Greek, Middle Eastern, South Asian, and African descent. Males and females have similar rates of disease. It resulted in 16,800 deaths in 2015, down from 36,000 deaths in 1990. Those who have minor degrees of thalassemia, similar to those with sickle-cell trait, have some protection against malaria, explaining why they are more common in regions of the world where malaria exists.

Browse All Tags